{"id":"mva-bn-standard-regimen","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"20-40","effect":"Myalgia"},{"rate":"20-35","effect":"Fatigue"},{"rate":"15-30","effect":"Headache"},{"rate":"5-15","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL6068545","moleculeType":"Small molecule","molecularWeight":"570.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) is a replication-competent orthopoxvirus vaccine derived from vaccinia virus. It expresses immunogenic proteins from monkeypox virus to elicit both cellular and humoral immune responses. The vaccine is designed to provide protection against monkeypox infection through activation of T-cell and B-cell mediated immunity.","oneSentence":"MVA-BN is a live attenuated vaccinia virus-based vaccine that stimulates immune responses against monkeypox virus antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:20.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Monkeypox prevention in at-risk populations"},{"name":"Post-exposure prophylaxis for monkeypox"}]},"trialDetails":[{"nctId":"NCT06844500","phase":"PHASE3","title":"Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-06-23","conditions":"Neonate, Maternal Transmission, Mpox","enrollment":359},{"nctId":"NCT06549530","phase":"PHASE2","title":"Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2024-10-21","conditions":"Monkeypox (Mpox)","enrollment":460},{"nctId":"NCT06844487","phase":"PHASE3","title":"Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-05-29","conditions":"Mpox (Monkeypox), Vaccination, Immunogenicity","enrollment":344},{"nctId":"NCT02038881","phase":"PHASE2","title":"Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2014-04-28","conditions":"Smallpox","enrollment":87},{"nctId":"NCT00082446","phase":"PHASE1","title":"Combination Study With MVA BN and Dryvax","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-05","conditions":"Smallpox","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MVA-BN standard regimen","genericName":"MVA-BN standard regimen","companyName":"Jean-Pierre Van geertruyden","companyId":"jean-pierre-van-geertruyden","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVA-BN is a live attenuated vaccinia virus-based vaccine that stimulates immune responses against monkeypox virus antigens. Used for Monkeypox prevention in at-risk populations, Post-exposure prophylaxis for monkeypox.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}